Marker Therapeutics, Inc.

Monthly Archives: September 2015

TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization JACKSONVILLE, Florida, September 15, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S.
Read More